Your privacy is important to us. Cookies are very small text files that are stored on your computer when you visit a website. We use cookies and other tracking technologies for a variety of purposes and to enhance your online experience on our website. You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website. You can check our privacy policy page for more information.
-
reportToday, there are more than 260 medicines in development for neurodegenerative diseases affecting millions of Americans. A new report from PhRMA explores these medicines that target these diseases and conditions.
Get your free copy of the report now.
As America’s aging population expands, so does the increasing need to address and conquer Alzheimer’s disease. It places significant burden on millions of Americans, their caregivers and our health care system as a whole. Despite challenges and setbacks, biopharmaceutical researchers have pushed forward in the search for lifesaving treatments and cures.
However, policies that would limit access to Alzheimer’s disease treatments, like the Centers for Medicare & Medicaid Services (CMS) proposed national coverage determination, are devastating for patients.
Dive deeper into the full list of more than 260 medicines currently in development for 29 neurodegenerative diseases.
This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.